|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cruz CS Dela, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hotta K, Kiura K, Ueoka H, Tabata M,
Fujiwara K, Kozuki T, Okada T, Hisamoto A and Tanimoto M: Effect of
gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with
advanced non-small-cell lung cancer. Lung Cancer. 46:255–261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burotto M, Manasanch EE, Wilkerson J and
Fojo T: Gefitinib and erlotinib in metastatic non-small cell lung
cancer: A meta-analysis of toxicity and efficacy of randomized
clinical trials. Oncologist. 20:400–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Engelman JA and Settleman J: Acquired
resistance to tyrosine kinase inhibitors during cancer therapy.
Curr Opin Genet Dev. 18:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prabhakar CN: Epidermal growth factor
receptor in non-small cell lung cancer. Transl Lung Cancer Res.
4:110–118. 2015.PubMed/NCBI
|
|
7
|
Chen J, Wang W, Wang H, Liu X and Guo X:
Combination treatment of ligustrazine piperazine derivate DLJ14 and
adriamycin inhibits progression of resistant breast cancer through
inhibition of the EGFR/PI3K/Akt survival pathway and induction of
apoptosis. Drug Discov Ther. 8:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ørom UA, Derrien T, Beringer M, Gumireddy
K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q,
et al: Long noncoding RNAs with enhancer-like function in human
cells. Cell. 143:46–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y,
Wei M, Chen J, Gao X, Xu C, et al: The prostate cancer-up-regulated
long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation
through reciprocal regulation of androgen receptor. Urol Oncol.
31:1117–1123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang F, Zhang L, Huo XS, Yuan JH, Xu D,
Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, et al: Long noncoding
RNA high expression in hepatocellular carcinoma facilitates tumor
growth through enhancer of zeste homolog 2 in humans. Hepatology.
54:1679–1689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and
De W: The long non-coding RNA HOTAIR indicates a poor prognosis and
promotes metastasis in non-small cell lung cancer. BMC Cancer.
13:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun M, Liu XH, Wang KM, Nie FQ, Kong R,
Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, et al: Down regulation of
BRAF activated non-coding RNA is associated with poor prognosis for
non-small cell lung cancer and promotes metastasis by affecting
epithelialmesenchymal transition. Mol Cancer. 13:682014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han L, Kong R, Yin DD, Zhang EB, Xu TP, De
W and Shu YQ: Low expression of long noncoding RNA GAS6-AS1
predicts a poor prognosis in patients with NSCLC. Med Oncol.
30:6942013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Zhou XF, Pan GF and Zhao JP:
Enhanced expression of long non-coding RNA ZXF1 promoted the
invasion and metastasis in lung adenocarcinoma. Biomed
Pharmacother. 68:401–407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ricciuti B, Mecca C, Crinò L, Baglivo S,
Cenci M and Metro G: Non-coding RNAs in lung cancer. Oncoscience.
1:674–705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas D and Livak KJ: Analyzing real-time
PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rahman AF, Korashy HM and Kassem MG:
Gefitinib. Profiles Drug Subst Excip Relat Methodol. 39:239–264.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pilkington G, Boland A, Brown T, Oyee J,
Bagust A and Dickson R: A systematic review of the clinical
effectiveness of first-line chemotherapy for adult patients with
locally advanced or metastatic non-small cell lung cancer. Thorax.
70:359–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan Y, Li XF, Chen JQ, Dong CX, Weng SS
and Huang JJ: Critical appraisal of the role of gefitinib in the
management of locally advanced or metastatic non-small cell lung
cancer. Onco Targets Ther. 7:841–852. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Zhu N and Chen X: A novel long
noncoding RNA LINC01133 is upregulated in lung squamous cell cancer
and predicts survival. Tumour Biol. 36:7465–7471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai H, Chen J, He B, Li Q, Li Y and Gao Y:
A FOXM1 related long non-coding RNA contributes to gastric cancer
cell migration. Mol Cell Biochem. 406:31–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao Y, Chen G, Zeng Y, Zeng J, Lin M, Liu
X and Liu J: Invasion and metastasis-related long noncoding RNA
expression profiles in hepatocellular carcinoma. Tumour Biol.
36:7409–7422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J,
Wei M, Xu C, Wu C, Zhang Z, et al: Long non-coding RNA metastasis
associated in lung adenocarcinoma transcript1 derived miniRNA as a
novel plasma-based biomarker for diagnosing prostate cancer. Eur J
Cancer. 49:2949–2959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L
and Yin R: CCAT2 is a lung adenocarcinoma specific long non-coding
RNA and promotes invasion of non-small cell lung cancer. Tumour
Biol. 35:5375–5380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng N, Li X, Zhao C, Ren S, Chen X, Cai
W, Zhao M, Zhang Y, Li J, Wang Q and Zhou C: Microarray expression
profile of long non-coding RNAs in EGFR-TKIs resistance of human
non-small cell lung cancer. Oncol Rep. 33:833–839. 2015.PubMed/NCBI
|
|
30
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitorsin non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li H, Schmid-Bindert G, Wang D, Zhao Y,
Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK
signaling pathways can overcome gefitinib-resistance in non-small
cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang XH, Xu ZY, Gong YB, Wang LF, Wang ZQ,
Xu L, Cao F and Liao MJ: Bufalin reverses HGF-induced resistance to
EGFR-TKIs in EGFR mutant lung cancer cells via blockage of
Met/PI3k/Akt pathway and induction of apoptosis. Evid Based
Complement Alternat Med. 2013:2438592013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qiao M, Sheng S and Pardee AB: Metastasis
and AKT activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Slack A, Chen Z, Tonelli R, Pule M, Hunt
L, Pession A and Shohet JM: The p53 regulatory gene MDM2 is a
direct transcriptional target of MYCN in neuroblastoma. Proc Natl
Acad Sci USA. 18:731–736. 2005. View Article : Google Scholar
|
|
36
|
Harris MH and Thompson CB: The role of the
Bcl-2 family in the regulation of outer mitochondrial membrane
permeability. Cell Death Differ. 7:1182–1191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Elkholi R, Renault TT, Serasinghe MN and
Chipuk JE: Putting the pieces together: How is the mitochondrial
pathway of apoptosis regulated in cancer and chemotherapy? Cancer
Metab. 2:162014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Muthu M, Cheriyan VT and Rishi AK:
CARP-1/CCAR1: A biphasic regulator of cancer cell growth and
apoptosis. Oncotarget. 6:6499–6510. 2015. View Article : Google Scholar : PubMed/NCBI
|
